Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13635257 | 0.93 | ESR2 (0.35) | ESR2PTGS2 | |
| SCHEMBL13635600 | 0.92 | PTGS2 (0.35) | ESR2PTGS2 | |
| SCHEMBL13635786 | 0.90 | ESR2 (0.38) | ESR2PTGS2PPARGPPARA | |
| SCHEMBL13635220 | 0.90 | PTGS2 (0.38) | ESR2PTGS2 | |
| SCHEMBL13632531 | 0.87 | PTGS2 (0.38) | ESR2PTGS2PPARGPPARA | |
| SCHEMBL13632499 | 0.85 | PTGS2 (0.37) | ESR2PTGS2PPARGPPARA | |
| SCHEMBL13632530 | 0.85 | PTGS2 (0.37) | ESR2PTGS2PPARGPPARA | |
| SCHEMBL14045797 | 0.82 | PTGS2 (0.41) | ESR2PTGS2 | |
| SCHEMBL13635052 | 0.82 | PTGS2 (0.38) | ESR2PTGS2 | |
| SCHEMBL4365677 | 0.81 | ESR2 (0.46) | ESR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | ESR2 1536/4885PTGS2 3/4885PPARG 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.